The program will target investments in animal-health therapeutics and technologies but could also support other life sciences startups.
Read More
The grant from the National Institutes of Health will allow researchers from the IU School of Medicine and the IU Luddy School of Informatics, Computing and Engineering to accelerate the search for new Alzheimer’s treatments.
Read More
No athlete wants to endure a torn knee ligament. But for OrthoIndy CEO Dr. Matthew Lavery, an injury playing football for Division III Millikin University sparked an interest in fixing other people’s injuries.
The procedure allows surgeons to make smaller incisions than are typically made in traditional mastectomies.
Former Chief Execution Officer Shane Hochradel resigned from Elevance in May and joined California-based Alignment Healthcare on June 1.
In January, the Centers for Medicare & Medicaid Services, or CMS, removed 285 procedures — mostly musculoskeletal, like revision hip and knee replacements — from its Medicare Inpatient-Only list.
After transforming the treatment of diabetes and weight loss, a growing body of research is raising the possibility that these drugs may help protect against cancer.
Trial patients who received the drug after surgery or radiation therapy experienced an 83% reduction in the risk of disease recurrence or death compared with those who received a placebo.
BE-101, soon to be known as Optavant, is expected to be commercially available in the third quarter of this year after it receives full licensure from the U.S. Department of Agriculture.
Rural hospitals in Indiana are facing a crisis that could lead to more health deserts across the state, hospital leaders say.
Dr. Scott D. Boden will succeed Dr. Jay Hess, one of the longest-serving medical school deans in the country.
CVS Caremark will add Foundayo coverage on June 1 and resume covering Zepbound on Oct. 1.
The Indianapolis-based drugmaker said some trial participants saw a level of weight loss similar to what patients experience after bariatric surgery.
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
Leaders of the technology company Hc1 planned a small conference that used the appeal of the upcoming Indianapolis 500 to bring together health care leaders from around the country for a few days.
At Crispus Attucks High School, students have many career-prep options through the school’s health care pathways program.
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
The Crossroads Academic Medical Institute, or CAMI, will connect universities, health systems and clinical training sites.
The name BioHeartland was created to give Indiana “a more cohesive and unified way to share the state’s story with investors, companies, researchers and talent around the world,” officials said.
Beta thalassemia major, also known as Cooley’s anemia and transfusion-dependent beta thalassemia, causes the body’s red blood cells to produce less hemoglobin than usual.
The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, detect and manage noncommunicable diseases in children and adolescents.
